APA (7th ed.) Citation

S, M., D, M., K, N., & Y, O. (2025). Identifying factors for pembrolizumab eligibility in head and neck cancer. Journal of cancer research and clinical oncology, 151(2), 67. https://doi.org/10.1007/s00432-025-06121-0

Chicago Style (17th ed.) Citation

S, Miyamaru, Murakami D, Nishimoto K, and Orita Y. "Identifying Factors for Pembrolizumab Eligibility in Head and Neck Cancer." Journal of Cancer Research and Clinical Oncology 151, no. 2 (2025): 67. https://doi.org/10.1007/s00432-025-06121-0.

MLA (9th ed.) Citation

S, Miyamaru, et al. "Identifying Factors for Pembrolizumab Eligibility in Head and Neck Cancer." Journal of Cancer Research and Clinical Oncology, vol. 151, no. 2, 2025, p. 67, https://doi.org/10.1007/s00432-025-06121-0.